+++ Trevena +++ Revolution in der Schmerztherapie? (Seite 162)
eröffnet am 04.01.18 20:37:22 von
neuester Beitrag 03.02.24 08:02:54 von
neuester Beitrag 03.02.24 08:02:54 von
Beiträge: 2.375
ID: 1.270.862
ID: 1.270.862
Aufrufe heute: 0
Gesamt: 280.116
Gesamt: 280.116
Aktive User: 0
ISIN: US89532E2081 · WKN: A3DWN1 · Symbol: TRVN
0,4073
USD
+1,83 %
+0,0073 USD
Letzter Kurs 17:52:43 Nasdaq
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,8900 | +101,55 | |
| 1,2099 | +34,52 | |
| 0,9500 | +33,67 | |
| 1,6500 | +32,00 | |
| 2,6802 | +27,02 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6100 | -15,26 | |
| 5,8100 | -17,47 | |
| 0,5190 | -19,30 | |
| 3,5000 | -26,24 | |
| 11,500 | -29,23 |
Beitrag zu dieser Diskussion schreiben
Feedback
Tja, wie man es macht ist es verkehrt. Also abschreiben und liegenlassen. Was soll‘s.
Antwort auf Beitrag Nr.: 59.126.855 von HH-ahoi2 am 02.11.18 19:11:42
so ein Mist- worst case
von welchem Zeitraum sprechen wir 1 -2 Jahre ?
L&S kracht gerade auf -47,83 % runter
Nicht approved
Habe mal einen Kaufauftrag zu 0,35 Euro abgegeben.
Trading Spotlight
O.k. Dsuvia ist durch, Oli in der Warteschleife...der Markt wird sicherlich überreagieren in den ersten Handelsminuten...wie will see.
Wie von dir vermutet Cyberhexe, CRL. Respekt 😏👍
Wann wird der Trading Halt aufgehoben & welche Kursreaktion erwartest du?
Danke 🙏
Wann wird der Trading Halt aufgehoben & welche Kursreaktion erwartest du?
Danke 🙏
Antwort auf Beitrag Nr.: 59.126.567 von Cyberhexe am 02.11.18 18:47:44
Consistent with the discussion at the recent Advisory Committee meeting, FDA has requested additional clinical data on QT prolongation and indicated that the submitted safety database is not of adequate size for the proposed dosing. FDA also requested certain additional nonclinical data and validation reports.
...das dauert!
Consistent with the discussion at the recent Advisory Committee meeting, FDA has requested additional clinical data on QT prolongation and indicated that the submitted safety database is not of adequate size for the proposed dosing. FDA also requested certain additional nonclinical data and validation reports.
...das dauert!
Antwort auf Beitrag Nr.: 59.126.516 von Cyberhexe am 02.11.18 18:40:17revena Receives Complete Response Letter for Oliceridine from FDA
GlobeNewswire•November 2, 2018
Company to host conference call and webcast on November 5th
CHESTERBROOK, Pa., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN) today announced the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for oliceridine.
“While we are disappointed with FDA’s decision, we continue to believe in the strength of the data and the ultimate approvability of oliceridine,” said Carrie L. Bourdow, President and Chief Executive Officer. “We plan to schedule a follow-up meeting with FDA as soon as possible with the goal of bringing this important medicine to clinicians and hospital patients.”
GlobeNewswire•November 2, 2018
Company to host conference call and webcast on November 5th
CHESTERBROOK, Pa., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN) today announced the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for oliceridine.
“While we are disappointed with FDA’s decision, we continue to believe in the strength of the data and the ultimate approvability of oliceridine,” said Carrie L. Bourdow, President and Chief Executive Officer. “We plan to schedule a follow-up meeting with FDA as soon as possible with the goal of bringing this important medicine to clinicians and hospital patients.”
Antwort auf Beitrag Nr.: 59.126.516 von Cyberhexe am 02.11.18 18:40:17Page Not Found
Durchsuchen
